• Medincell published a press release noting Teva’s U.S. net sales of UZEDY reached a record USD 77 million in Q2 2026, up 43% year on year.
• Teva raised its 2026 UZEDY sales outlook to USD 270 million-USD 290 million from USD 250 million-USD 280 million.
• Medincell said it receives mid- to high-single-digit royalties on net sales, with eligibility for USD 105 million in commercial milestones.
• FDA action on Teva’s monthly long-acting olanzapine injection is expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.